Blood tests are a familiar part of medical care. Most patients expect them. For mesothelioma, certain blood tests can support diagnosis, monitor disease, and complement other tests, though no single blood test confirms or rules out the disease on its own.
This guide explains the mesothelioma blood tests and biomarkers used in clinical practice today. You will learn what each test measures, what its strengths and limitations are, and how it fits into the broader diagnostic and monitoring picture.
Mesomark and Soluble Mesothelin-Related Peptide
The most established mesothelioma blood biomarker is soluble mesothelin-related peptide, abbreviated SMRP. Mesothelin is a protein expressed on mesothelial cells. Mesothelioma tumours often shed mesothelin into the bloodstream, where it can be measured. The Mesomark test is the FDA-approved assay for SMRP.
Elevated SMRP supports a mesothelioma diagnosis when other findings are suspicious. Lower levels do not rule out mesothelioma because some tumours, particularly sarcomatoid types, do not produce mesothelin. The test is most useful as part of a panel including imaging, biopsy, and other markers, not as a standalone test.
SMRP can also track disease activity over time. Decreasing levels during treatment suggest response. Rising levels can suggest progression and may prompt restaging imaging earlier than the routine schedule.
Fibulin-3
Fibulin-3 is another biomarker that has shown elevation in pleural mesothelioma. Studies have evaluated it both in blood and in pleural fluid. The diagnostic accuracy varies across studies. Fibulin-3 is not as widely used as SMRP and is not FDA-approved as a standalone diagnostic test, but it is sometimes measured alongside SMRP at major research centres.
The combination of multiple biomarkers may improve diagnostic accuracy beyond any single marker. Research continues to refine the optimal panel.
Osteopontin and Megakaryocyte Potentiating Factor
Two other biomarkers studied in mesothelioma are osteopontin and megakaryocyte potentiating factor, or MPF. Both have shown some diagnostic utility in research settings. Neither has reached widespread clinical use comparable to SMRP. Specialty centres may include them in panels for specific diagnostic situations.
The history of biomarker development for mesothelioma reflects the difficulty of finding markers that are sensitive enough to catch early disease and specific enough to avoid false positives. None of the available markers fully solves both problems.
Standard Blood Tests Routinely Ordered
Beyond mesothelioma-specific biomarkers, several routine blood tests are ordered throughout treatment. Complete blood count tracks red cells, white cells, and platelets, which are all affected by chemotherapy. Comprehensive metabolic panels track kidney and liver function. These tests are drawn at every cycle of chemotherapy and are essential for safe treatment delivery.
Tumour markers from other cancer panels, like CA 125 or carcinoembryonic antigen, may be elevated in some mesothelioma patients but are not specific for the disease. They are sometimes used as monitoring tools when their initial level was clearly elevated.
Liquid Biopsy and Circulating Tumour DNA
The frontier of mesothelioma blood-based diagnostics is liquid biopsy, which uses blood samples to detect circulating tumour DNA. The DNA fragments released by dying tumour cells can be analysed for cancer-specific mutations. Liquid biopsy is increasingly used in many cancers for monitoring response, detecting resistance mutations, and identifying minimal residual disease after treatment.
For mesothelioma, liquid biopsy applications are still developing. The technology is being studied for monitoring response to immunotherapy, detecting recurrence early, and identifying patients who would benefit from specific targeted therapies. Patients at major centres may have liquid biopsy performed as part of clinical trials or research protocols.
Insurance and Cost
The Mesomark test for SMRP is generally covered by major insurers when ordered for an appropriate clinical indication. Coverage for newer biomarkers and liquid biopsy applications varies more widely. Out-of-pocket costs for niche tests can range from several hundred to several thousand dollars when not covered.
Always verify coverage before tests are ordered, particularly for non-standard panels. Specialty centres often handle the verification but it is worth confirming. Surprise lab bills are a common source of frustration in cancer care.
A Realistic Note on Limitations
Despite years of research, no blood test today is sensitive and specific enough to diagnose mesothelioma without imaging and biopsy. The biomarkers we have are useful adjuncts. They are not replacements. Anyone offering a “mesothelioma blood test that confirms diagnosis” without other workup is overselling the technology.
That said, biomarkers add real information when used alongside other tests. Trends over time can be informative. Initial values can support clinical impressions. The thoughtful integration of blood-based and imaging-based tests is part of high-quality mesothelioma treatment at experienced centres.
Closing Note
Ask your oncologist which blood-based tests they routinely use in your monitoring plan and what changes in those values would prompt action. The answers help you participate in your own care. They also help you avoid unnecessary anxiety about minor fluctuations that are not clinically significant.
The field is evolving. New tests are coming. The biomarker landscape for mesothelioma in 2030 will likely look different than today’s. For now, the established tools described above represent the practical state of the art.
This article is for educational purposes and does not replace personalised guidance from a treating oncologist.